ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharma's subsidiary Apnar Pharma completed a USFDA inspection at its Vadodara facility with no GMP observations. Only one minor procedural finding was noted.
Senores Pharmaceuticals issued a corrigendum to its FY 2025-26 Annual Report to rectify typographical errors in the narrative and Director's Report sections. The original report remains valid.
Senores Pharmaceuticals Ltd submitted its Annual Report for FY 2025-26 and notice for its 9th Annual General Meeting scheduled for September 25, 2026.
Senores Pharmaceuticals Limited plans to incorporate a new entity in Canada for pharmaceutical supply and distribution. The company will hold a majority 51% stake.
Senores Pharmaceuticals appointed Shilpa Sharma as Company Secretary and Viranchi Arvindbhai Shah as Independent Director. The board also approved a new ESOP scheme.
Senores Pharmaceuticals has issued a ₹62 Crore corporate guarantee to ICICI Bank to secure credit facilities for its subsidiary, Apnar Pharma Private Limited.
Promoter Dhananjay Ashokkumar Barot disposed of 30,000 shares (0.06% stake) of Senores Pharmaceuticals Limited via an off-market inter-se gift transfer.
Promoter Ashokkumar Vijaysinh Barot acquired 30,000 shares of Senores Pharmaceuticals via an off-market inter-se gift. The acquisition increases his stake by 0.06%.
Senores Pharmaceuticals Ltd informed the exchange that shareholders approved ordinary and special resolutions via postal ballot, including related party transactions and loan limit enhancements.
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations for the period ended June 30, 2026.
Senores Pharmaceuticals delivered strong Q1 FY27 growth, doubling approved ANDAs to 58. Management is pivoting strategy toward profitability in domestic branded generics while scaling US operations via new specialized subsidiaries.
Senores Pharmaceuticals Limited has appointed Ms. Anjali Shah as Assistant Vice President - Finance, effective July 27, 2026. She brings over 10 years of experience in finance.
Senores Pharmaceuticals delivered robust Q1FY27 performance with revenue growing 36% and EBITDA 87% YoY, driven by strong growth in regulated markets and margin expansion of ~800 bps.
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180 crore, with EBITDA at ₹54 crore and PAT of ₹31 crore. Strong performance was driven by regulated markets.
Senores Pharmaceuticals Ltd reported revenue from operations of ₹180.2 Cr (+35.9% YoY) and net profit of ₹30.4 Cr (+43.4% YoY) for Q1 FY27.
Senores Pharmaceuticals scheduled a board meeting for July 27, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026.
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern. The document details equity holdings across promoters, institutions, and public shareholders.
Senores Pharmaceuticals has issued a Postal Ballot Notice to shareholders for approval of related party transactions. Voting concludes August 3, 2026, with results announced by August 5.
Senores Pharmaceuticals approved revised utilisation of ₹100 Crore from unutilised IPO proceeds. The change is subject to shareholder approval via postal ballot.
Senores Pharmaceuticals announced the cessation of its Company Secretary and Compliance Officer effective June 10, 2026. The company has designated other KMPs for disclosure responsibilities.
Senores Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed general compliance with SEBI regulations and secretarial standards.
Senores Pharmaceuticals delivered a blockbuster FY26, significantly outperforming guidance with 62% revenue growth and 108% PAT growth, driven by US regulated market expansion.
Senores delivered a massive FY26 beat across all primary metrics, fueled by aggressive US ANDA acquisitions and product launches. Management is hyper-optimistic, raising FY27 guidance significantly despite global logistical headwinds.
Senores Pharmaceuticals issued a corrigendum to its FY26 media release to rectify a typing error. Revised financial highlights show consolidated total income of ₹664 Crore.
Senores Pharmaceuticals delivered strong FY26 performance with Total Income at ₹664 cr (+62% YoY) and PAT at ₹121.5 cr (+108% YoY), driven by regulated market scaling and strategic acquisitions.
Senores Pharmaceuticals Limited submitted its Monitoring Agency Report for the Rs.500 Crore IPO proceeds. The filing confirms fund deployment for objects including debt repayment and growth.
Senores Pharmaceuticals reported Q4FY26 total income of ₹190 Crore, up 66% year-on-year. Strong performance was driven by regulated market growth and recent US-based acquisitions.